New Research Study for Patients With Ulcerative Colitis Now Available in Ogden, Utah

Adults with ulcerative colitis (UC) may be eligible to join a clinical trial to evaluate an investigational oral medication for its potential to bring about long-term remission.

BOSTON — (BUSINESS WIRE) — Adults in the Ogden, Utah area with moderately to severely active ulcerative colitis (UC) may have the opportunity to join a research study assessing a new investigational medication. UC is the most common form of inflammatory bowel disease (IBD), affecting an estimated 5 million people worldwide.

There is no known cure for UC, though new therapies have become available in recent years that offer patients improved treatment options. Current treatments for UC offer relief for many individuals, but some still face recurrent flare-ups or undesirable side effects. The ANTHEM-UC study from Janssen Research & Development seeks to assess if an investigational pill could help those patients whose UC is not adequately managed by currently available therapies.

“Ulcerative colitis is a lifelong condition that often gets worse over time, potentially causing severe flare-ups or hospitalization,” said Dr. Chad Gonzales, Principal Investigator at Care Access - Ogden.

The study is now enrolling for adults age 18 or older with moderately to severely active UC, who have not responded well to currently available therapies. To learn more, visit or contact Care Access at (351) 222-5112.

Care Access opened its doors in Ogden in collaboration with local community leaders and healthcare providers seeking to make clinical studies more easily accessible to patients. The local setting provides residents of Ogden and surrounding communities the option to participate in clinical studies close to home.